Diabetes

  • The role of SGLT-2 inhibitors in managing type 2 diabetes
    Yumiko Tsushima, MD, M. Cecilia Lansang, MD, MPH and Vinni Makin, MBBS, MD, FACE
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 47-58; DOI: https://doi.org/10.3949/ccjm.88a.20088

    These drugs improve glycemic control and offer cardiovascular and metabolic benefits.

  • SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
    Jonathan J. Taliercio, DO, George Thomas, MD, Georges N. Nakhoul, MD, MEd, Tushar J. Vachharajani, MD and Ali Mehdi, MD, MEd
    Cleveland Clinic Journal of Medicine January 2021, 88 (1) 59-63; DOI: https://doi.org/10.3949/ccjm.88a.20190

    Randomized controlled trials of these new agents had positive outcomes.

  • Peripheral artery disease and unusual skin findings
    Aaron Andrew Heigaard Smith, MD, Erin Luxenberg, MD and Roberta Meyers, MD, MPH
    Cleveland Clinic Journal of Medicine October 2020, 87 (10) 605-612; DOI: https://doi.org/10.3949/ccjm.87a.19074

    A 68-year-old man was admitted because of worsening skin problems in his legs.

  • Familial hypercholesterolemia: Clarifications
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 320; DOI: https://doi.org/10.3949/ccjm.87c.06001

    Comments on xanthoma vs xanthelasmas, and goal LDL-C.

  • In Reply: Familial hypercholesterolemia: Clarifications
    Nishant P. Shah, MD,FACC, Haitham M. Ahmed, MD and W. H. Wilson Tang, MD
    Cleveland Clinic Journal of Medicine June 2020, 87 (6) 320; DOI: https://doi.org/10.3949/ccjm.87c.06002

    The authors' response.

  • Diabetes management
    Cleveland Clinic Journal of Medicine November 2019, 86 (11) 760;

    Information was omitted from Table 1 on page 596 of the article, Makin V, Lansang MC. Diabetes management: Beyond hemoglobin A1c. Cleve Clin J Med 2019; 86(9):595–600. doi:10.3949/ccjm.86a.18031

  • Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 573-574; DOI: https://doi.org/10.3949/ccjm.86b.09019

    As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.

  • Diabetic dyslipidemia with eruptive xanthoma
    Yu-Chun Hsueh, MD, Chuan-Liang Chou, MD and Ting-I. Lee, MD, PhD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 575-576; DOI: https://doi.org/10.3949/ccjm.86a.18104

    Off medications for 1 year, her triglyceride level was 10,250 mg/dL, hemoglobin A1c 12.4%.

  • Diabetes management: Beyond hemoglobin A1c
    CME article
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

  • In reply: Gastroparesis
    Ahmad Muneer Sharayah, MD, Noor Hajjaj, MD, Ramy Osman, MD and Douglas Livornese, MD
    Cleveland Clinic Journal of Medicine August 2019, 86 (8) 514; DOI: https://doi.org/10.3949/ccjm.86c.08002

Pages